ZLc002
- CAS No.
- 308277-46-5
- Chemical Name:
- ZLc002
- Synonyms
- ZLc002;EX-A5758;(S)-ZLc002;EX A5758,EXA5758;Methyl (3-methoxy-3-oxopropanoyl)-L-valinate;L-Valine, N-(3-methoxy-1,3-dioxopropyl)-, methyl ester
- CBNumber:
- CB69933477
- Molecular Formula:
- C10H17NO5
- Molecular Weight:
- 231.25
- MDL Number:
- MOL File:
- 308277-46-5.mol
Boiling point | 350.1±22.0 °C(Predicted) |
---|---|
Density | 1.115±0.06 g/cm3(Predicted) |
storage temp. | Store at -20°C |
solubility | DMSO: 46 mg/mL (198.92 mM);Ethanol: 46 mg/mL (198.92 mM) |
pka | 12.22±0.46(Predicted) |
form | Solid |
color | Off-white to light yellow |
Water Solubility | Water: 46 mg/mL (198.92 mM) |
InChI | InChI=1S/C10H17NO5/c1-6(2)9(10(14)16-4)11-7(12)5-8(13)15-3/h6,9H,5H2,1-4H3,(H,11,12)/t9-/m0/s1 |
InChIKey | BWPKYDAJBOUZDX-VIFPVBQESA-N |
SMILES | C(OC)(=O)[C@H](C(C)C)NC(=O)CC(OC)=O |
ZLc002 Chemical Properties,Uses,Production
Biological Activity
ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain.
Biological Functions
ZLc002, a putative small-molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability. It could disrupt binding between nNOS and NOS1AP using ex-vivo, in vitro, and purified recombinant systems. In vitro, ZLc002 reduced coimmunoprecipitation of full-length NOS1AP and nNOS in cultured neurons and HEK293T cells co-expressing full-length nNOS and NOS1AP[1].
References
[1] Lee WH, et al. Mol Pain. 2018 Jan-Dec;14:1744806918801224.
[2] Wan-Hung Lee. “ZLc002, a putative small-molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability.” Molecular Pain 14 (2018): 1744806918801224.
ZLc002 Preparation Products And Raw materials
Raw materials
Preparation Products
ZLc002 Suppliers
Supplier | Tel | Country | ProdList | Advantage | |
---|---|---|---|---|---|
Shenyang Zhongshen Zekang Biomedical Technology Research Co., Ltd | +86-18341751992 +86-15382112998 | 757984502@qq.com | China | 892 | 58 |
Nantong HI-FUTURE Biology Co., Ltd. | +undefined18051384581 | sales@chemhifuture.com | China | 3136 | 58 |
TargetMol Chemicals Inc. | +1-781-999-5354 | support@targetmol.com | United States | 19973 | 58 |
Wuhan Jingkang en Biomedical Technology Co., Ltd | +8613720134139 | orders@jknbiochem.com | China | 5225 | 58 |
Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | info@efebio.com | China | 9806 | 58 |
Shanghai Han-Xiang Chemical Co., Ltd. | 15971444841 | amber@biochempartner.com | China | 3063 | 58 |
Shandong Jirun Biomedical Technology Co., Ltd. | 0539-0539-8613587 17661611089 | 2639273505@qq.com | China | 165 | 58 |
ShangHai ChuanQian Chemcial Technique Centre | 15869524721 | 3525679403@qq.com | China | 3852 | 58 |
Nantong Hi-Future Biotechnology Co., Ltd | 18051384581 | sales@chemhifuture.com | China | 3057 | 58 |
Bide Pharmatech Ltd. | 400-1647117 13681763483 | product02@bidepharm.com | China | 62163 | 58 |